Skip to content
The Nexus
DossierENTITY

neuroimmune therapies

Coverage of neuroimmune therapies in the Nexus archive.

Earliest in view: Jun 22 · 21:00 UTCMost recent: Jun 22 · 21:00 UTC
Co-mentioned in this coverage
Insilico Medicineorganization1SK Biopharmaceuticalsorganization1Pharma.AItopic1Alex Zhavoronkovperson1Donghoon Leeperson1SK Grouporganization1Eli Lillyorganization1
Recent coverage
  • BUSINESSJun 22 · 21:00 UTCFORTUNE
    Insilico Medicine, SK Biopharmaceuticals strike $2.5B AI drug discovery deal targeting neuroimmune therapies

    Insilico Medicine and SK Biopharmaceuticals signed a $2.5B partnership to develop neuroimmune therapies using AI-driven drug discovery. Insilico will design candidates via its Pharma.AI platform, while SK Biopharmaceuticals handles late-stage development and commercialization. The deal includes potential milestone payments and royalties, marking Insilico's largest Asia-Pacific collaboration.

neuroimmune therapies · Dossier · The Nexus